title: Identification of anti-thrombin antibodies in the antiphospholipid syndrome that interfere with the inactivation of thrombin by antithrombin.
abstract: The combined presence of anti-phospholipid (PL) Ab, including lupus anticoagulants (LAC) and/or anticardiolipin Ab (aCL), and thrombosis is recognized as the antiphospholipid syndrome (APS). LAC are detected as an inhibitory effect on PL-restricted in vitro blood coagulation tests, and are comprised mainly of Ab against beta(2) glycoprotein I and prothrombin (PT). Recently, anti-PT Ab (aPT) were found to be associated with thrombosis by some investigators, although this is not confirmed by others. Considering that aPT are heterogeneous in patients and that PT is converted into thrombin, we hypothesize that certain aPT in patients may bind to thrombin, and that some of such anti-thrombin Ab may interfere with thrombin-antithrombin (AT) interaction and thus reduce the AT inactivation of thrombin. To test this hypothesis, we searched for anti-thrombin Ab in APS patients and then studied those found for their effects on the AT inactivation of thrombin. The results revealed that most, but not all, aPT-positive patient plasma samples contained anti-thrombin Ab. To study the functional significance of these Ab, we identified six patient-derived mAb that bound to both PT and thrombin. Of these mAb, three could reduce the AT inactivation of thrombin, whereas others had minimal effect. These findings indicate that some aPT in patients react with thrombin, and that some of such anti-thrombin Ab could inhibit feedback regulation of thrombin. Because the latter anti-thrombin Ab are likely to promote clotting, it will be important to develop specific assays for such Ab and study their roles in thrombosis in APS patients.
authors.affiliation: Division of Rheumatology, Department of Medicine, University of California, Los Angeles, CA 90095, USA. hwangkk@ucla.edu
authors.forename: K K
authors.initials: KK
authors.lastname: Hwang
authors.forename: J M
authors.initials: JM
authors.lastname: Grossman
authors.forename: S
authors.initials: S
authors.lastname: Visvanathan
authors.forename: R U
authors.initials: RU
authors.lastname: Chukwuocha
authors.forename: V L
authors.initials: VL
authors.lastname: Woods
authors.forename: D T
authors.initials: DT
authors.lastname: Le
authors.forename: B H
authors.initials: BH
authors.lastname: Hahn
authors.forename: P P
authors.initials: PP
authors.lastname: Chen
mesh_terms: D000293:Adolescent; D000328:Adult; D000911:Antibodies, Monoclonal / Q000276:immunology; D016736:Antiphospholipid Syndrome / Q000097:blood* / Q000150:complications / Q000276:immunology*; D000991:Antithrombins / Q000378:metabolism*; D001323:Autoantibodies / Q000276:immunology*; D001667:Binding, Competitive; D002648:Child; D003429:Cross Reactions; D004305:Dose-Response Relationship, Drug; D004797:Enzyme-Linked Immunosorbent Assay; D000939:Epitopes / Q000276:immunology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011516:Prothrombin / Q000276:immunology; D013917:Thrombin / Q000276:immunology* / Q000378:metabolism*; D013927:Thrombosis / Q000209:etiology
chemical_list: D000911:Antibodies, Monoclonal; D000991:Antithrombins; D001323:Autoantibodies; D000939:Epitopes; D011516:Prothrombin; D013917:Thrombin